Pharma BD Deal Intelligence
The $16B acquisition that gave Amgen full control of Enbrel, the anti-TNF biologic peaking at $5B+ in annual US sales. Completed during the 2002 biotech downturn, the deal was Amgen's transformational immunology bet that paid off for over a decade before biosimilar competition arrived.
Enbrel mega-deal built Amgen into global biotech leader with 30-year franchise
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Amgen agrees to buy Immunex in record biotech deal valued at about $16 billion in cash and stock.
The FTC cleared the $16 billion acquisition of Immunex Corporation by Amgen Inc., resolving anticompetitive concerns in the market for colony stimulating…
Amgen Inc. filed Form 8-K reporting the completion of its acquisition of Immunex Corporation.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Amgen acquired Immunex for approximately $16 billion in stock and cash, gaining full rights to Enbrel (etanercept), the blockbuster anti-TNF therapy for rheumatoid arthritis. The deal was 85% stock (0.44 Amgen shares per Immunex share) and 15% cash ($4.50 per share).
7.5M US cases/yr · $2.5B Global Psoriasis Market (2002)
Psoriasis and psoriatic arthritis affect approximately 7.5 million Americans combined. Enbrel received expanded approvals for psoriatic arthritis (2002) and moderate-to-severe plaque psoriasis (2004), significantly broadening its addressable patient population and commercial potential.
Enbrel's sequential label expansions into psoriatic arthritis and plaque psoriasis demonstrated the lifecycle management potential that justified the $16B premium. Each new indication added hundreds of millions in annual revenue to the franchise.
1.3M US cases/yr · $5.0B Global RA Market (2002)
Rheumatoid arthritis affected approximately 1.3 million US adults in 2001. The emergence of anti-TNF biologics in the late 1990s transformed RA treatment. Enbrel (etanercept) was among the first biologics approved for RA, pioneering the multi-billion-dollar TNF inhibitor class.
Amgen's $16B acquisition of Immunex was the largest biotech M&A at the time, driven entirely by Enbrel's commercial trajectory. The drug grew from $1.1B (2001) to $4.5B peak, validating the premium. The deal established Amgen as a diversified biotech leader beyond erythropoietin and GCSF.
Amgen Inc. closes acquisition/merger of Immunex Corporation for $16.0B, establishing strategic position and initiating integration.
Amgen acquired Immunex for $16B gaining Enbrel which generated peak sales exceeding $5B annually with patent protection potentially extending to 2029.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / Immunex Corporation (this deal) | 2001 | $16.0B | 91 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| Amgen Inc. / Otezla (from Celgene/BMS) | 2019 | $13.4B | 68 |
| Amgen Inc. / BeiGene Ltd. | 2020 | $2.8B | 68 |
← Browse all deals · How we score deals
More: 2001 deals · Amgen Inc. deals · Dermatology deals